Biogen (NASDAQ:BIIB) reported Q1 2018 earnings this Morning, coming in at $6.05 per share, beating Wall Street’s estimates of $5.93 per Share. Revenue for the quarter came in at $3.13 billion missing the streets estimates of $3.15 billion Recent Insider Trading for Biogen (NASDAQ:BIIB)
- On 2/27/2018 Alfred Sandrock, EVP, sold 259 with an average share price of $290.83 per share and the total transaction amounting to $75,324.97.
- On 2/20/2018 Alfred Sandrock, EVP, sold 743 with an average share price of $292.00 per share and the total transaction amounting to $216,956.00.
- On 2/15/2018 Alfred Sandrock, EVP, sold 1,294 with an average share price of $298.85 per share and the total transaction amounting to $386,711.90.
- On 1/9/2018 Robert W Pangia, Director, sold 5,832 with an average share price of $329.65 per share and the total transaction amounting to $1,922,518.80.
- On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
- On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
Dividend History for Biogen (NASDAQ:BIIB)
Recent Trading for Biogen (NASDAQ:BIIB) Shares of Biogen closed the previous trading session at 253.41 down -5.89 2.27% with 56971 shares trading hands.